Clene Inc., a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025. The event, taking place at The Plaza Hotel in New York City, will provide a platform for the company to engage with investors and share insights into its groundbreaking research.
President and CEO Rob Etherington will be available for one-on-one meetings from 9 a.m. to 3 p.m. ET, offering potential investors and stakeholders direct access to the company's leadership. This conference presents a significant opportunity for Clene to showcase its innovative approach to treating neurological conditions such as amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
The company's primary investigational therapy, CNM-Au8®, represents a novel approach to neurological treatment. By targeting mitochondrial function and the NAD pathway while reducing oxidative stress, CNM-Au8® aims to improve central nervous system cells' survival and function. This unique mechanism potentially offers new hope for patients suffering from challenging neurodegenerative disorders.
For investors and healthcare professionals, Clene's participation in this conference signals the company's commitment to transparency and continued advancement in neurological disease research. The one-on-one meeting format allows for direct communication about the company's scientific progress, potential therapeutic breakthroughs, and strategic vision.
